Boston Scientific (BSX) Debt to Equity (2009 - 2026)

Boston Scientific has disclosed Debt to Equity across 18 years of filings, most recently posting $0.42 for Q1 2026.

• Debt to Equity for Q1 2026 came in at $0.42, down 16.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.42 (down 16.14% YoY), and the FY2025 annual result was $0.47, down 4.4% from the prior year.
• Debt to Equity came in at $0.42 for Q1 2026 at Boston Scientific, down from $0.47 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $66.48 in Q2 2024 to a low of -$312.32 in Q1 2024.
• The 5-year median for Debt to Equity is $0.47 (2023), against an average of -$18.51.
• Across the five-year window, Debt to Equity slumped 195.83% in 2022 and jumped 1753.11% in 2024, its largest moves.
• Boston Scientific's Debt to Equity stood at -$11.91 in 2022, then jumped by 103.91% to $0.47 in 2023, then rose by 5.91% to $0.49 in 2024, then fell by 4.4% to $0.47 in 2025, then declined by 10.47% to $0.42 in 2026.
• The last three Debt to Equity figures came in at $0.42 (Q1 2026), $0.47 (Q4 2025), and $0.49 (Q3 2025), per Business Quant data.